

Dear Editors and Reviewers,

Thank you for your E-mail and for the reviewers' comments concerning our manuscript entitled "Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t (11;14) A case report" (ID: 60323). Those comments are very valuable and helpful for revising and improving our paper. We have studied comments carefully and have made corrections which we hope meet with approval. The main corrections in the paper and the responds to the reviewers' comments are as following:

Reviewer #1:

<1> The patient was 52 at first diagnosis, is now 57, but in the discussion she is 62.

Sorry, We made clerical mistakes in Case Summary. The patient was 57 at first diagnosis, is now 62. We have made corrections in the revised manuscript. We have revised "a 57-year-old woman" in Case Summary.

<2> It is not well described, why which regimen was chosen (e.g. why RD/VRD alternatively as maintenance therapy)

We have added to the reason about RD/VRD alternatively as maintenance therapy. We have added that "Considering the side effects of bortezomib, VRD is used every three months" in Treatment.

<3> Side effects are not always reported

Thanks for the Reviewer's suggestion. We have added side effects in our revised manuscript. We have added that "The patient's treatment-related side effects were incomplete intestinal obstruction and mild diarrhea" in Treatment.

<4> It is not described if the patient was re-evaluated for changes in cytogenetics or molecular alterations.

The patient was re-evaluated for changes in cytogenetics and molecular alterations before using Selinexor (XPO1 inhibitor)/dexamethasone regimen. Her FISH test remained the same as that when the disease was first diagnosed. This manuscript has

already mentioned in Treatment.

<5> Moreover, it is not described, why this patient never received carfilzomib or pomalidomid.

There was limited access to Carfilzomi or Pomalimidone in China.

EDITORIAL OFFICE' S COMMENTS:

Science editor:

<1> The language classification is Grade C.

We have uploaded a language editing certificate issued by MedSci.

<2>The authors did not provide original pictures. Please provide the original figure documents.

We have uploaded original figure documents.

<3>Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor.

We have prepared and arranged the figures using PowerPoint.

We have revised the manuscript according to format of World Journal of Clinical Cases.

With best regards,

Yours sincerely,

Dr. Meiwei Hu,

Department of Hematology,

The Second Affiliated Hospital of Zhejiang Chinese Medicine University,

No. 318 Chaowang Road,

Hangzhou 310014,

China

E-mail: humweiwei@sina.cn